Our most successful product to date is the ArrayPlate technology, a process for performing high throughput screening using patterns of gene expression as the readout. This allows screening for compounds that affect the transcription of a group of genes (directly or indirectly), while testing for affects on control genes at the same time. Founders, Drs Kris and Felder, are the co inventors and authors of the three umbrella patents for the technology, US 6,232,066, US 6,238,869 and US 7,659,063.
The ArrayPlate technology was sold to HTG, Inc. (High Throughput Genomics), started in 1997. It remains the major IP platform for HTG, and it has been licensed to several large and midsized pharmaceutical companies. NuvoGen Research retains the right to use ArrayPlate for cancer research.